FLLL32

FLLL32 is a novel small molecule analog of curcumin, specifically designed to inhibit the Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3) signaling pathway. It reduces STAT3 phosphorylation at Tyr705 (pSTAT3) and induces caspase-dependent apoptosis in cancer cells, demonstrating higher potency and greater specificity for STAT3 compared to curcumin[1][10]. FLLL32 has shown activity in multiple cancer cell lines, including melanoma, breast cancer, pancreatic cancer, oral cancer, and others, and has also been investigated for anti-inflammatory and antiparasitic effects[1][6][5]. It was developed as a lead compound for further optimization in drug development, particularly for cancers with constitutive STAT3 signaling, but currently remains in preclinical investigation[1][10].